|
Demographics and medical history
|
n (%) or mean±SD
|
N
|
|
Age, years
|
61.2±14.6
|
797
|
|
Male
|
431 (54.0)
|
798
|
|
BMI, kg/m2
|
34.5±8.4
|
796
|
|
Race*
|
American Indian or Alaskan Native
|
3 (0.4)
|
780
|
|
Asian
|
5 (0.6)
|
780
|
|
Black or African American
|
192 (24.6)
|
780
|
|
Native Hawaiian or Pacific Islander
|
1 (0.1)
|
780
|
|
White
|
571 (73.2)
|
780
|
|
Other
|
9 (1.2)
|
780
|
|
Hispanic or Latino ethnicity
|
18 (2.5)
|
717
|
|
History of DVT
|
143 (17.9)
|
797
|
|
History of PE
|
85 (10.7)
|
798
|
|
History of PHTN
|
77 (9.7)
|
793
|
|
History of cancer
|
165 (20.7)
|
798
|
|
Active cancer
|
65 (8.1)
|
798
|
|
Clinical presentation
|
n (%) or mean±SD
|
N
|
|
Duration of current PE symptoms, days
|
2.6±6.6
|
784
|
|
Failed prior therapy for current PE†
|
40 (5.2)
|
771
|
|
Anticoagulation
|
36 (90.0)
|
40
|
|
Thrombolysis, systemic
|
4 (10.0)
|
40
|
|
Thrombolysis, catheter-directed
|
2 (5.0)
|
40
|
|
Other mechani cal thrombectomy
|
3 (7.5)
|
40
|
|
Lytics contraindication
|
256 (32.1)
|
797
|
|
Absolute
|
31 (12.2)
|
255
|
|
Relative
|
224 (87.8)
|
255
|
|
PE risk stratification
|
High-risk PE
|
63 (7.9)
|
797
|
|
Intermediate-risk PE
|
734 (92.1)
|
797
|
|
Intermediate-high
|
611 (83.2)
|
734
|
|
Intermediate-low
|
59 (8.0)
|
734
|
|
Intermediate (not further classified)
|
64 (8.7)
|
734
|
|
sPESI score
|
1.6±1.1
|
751
|
|
sPESI = 0
|
123 (16.4)
|
751
|
|
sPESI ≥1
|
628 (83.6)
|
751
|
|
PE location at screening
|
Saddle PE
|
319 (40.0)
|
798
|
|
Unilateral PE
|
68 (8.5)
|
798
|
|
Bilateral PE
|
411 (51.5)
|
798
|
|
Concomitant DVT
|
512 (65.0)
|
788
|
|
Proximal only
|
152 (29.9)
|
508
|
|
Distal only
|
266 (52.4)
|
508
|
|
Both
|
90 (17.7)
|
508
|
|
Positive biomarker(s)‡
|
720 (94.6)
|
761
|
|
RV/LV ratio (CTPA)
|
1.56±0.47
|
624
|
|
RV/LV ratio (echo)
|
1.23±0.36
|
582
|
|
RV/LV ratio (CTPA or echo composite§)
|
1.50±0.46
|
756
|
|
Elevated RV/LV ratio>0.9
|
734 (97.1)
|
756
|
|
Depressed cardiac index (<2.0 L/min/m2)
|
176 (25.9)
|
680
|
|
Severe PHTN (sPAP ≥70 mmHg)
|
99 (12.7)
|
781
|
|
*One patient was multiracial (Black and Native Hawaiian or Pacific Islander). †In some patients, more than one prior therapy was attempted. ‡Positive biomarkers include elevated brain natriuretic peptide and/or cardiac troponins. §Composite used either CTPA or echo measurements, with CTPA prioritised if both were available. BMI: body mass index; CTPA: computed tomography pulmonary angiography; DVT: deep vein thrombosis; echo: echocardiogram; LV: left ventricle; PE: pulmonary embolism; PHTN: pulmonary hypertension; RV: right ventricle; SD: standard deviation; sPAP: systolic pulmonary artery pressure; sPESI: simplified Pulmonary Embolism Severity Index
|
